(PharmaNewsWire.Com, September 28, 2017 ) Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Pancreatic Cancer, Blood Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Leukemias, Lymphoma, Melanoma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).
The latest report Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Pipeline Review, H2 2017, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Eli Lilly and Company, H2 2017 Pipeline by Millennium Pharmaceuticals Inc, H2 2017 Pipeline by Nerviano Medical Sciences Srl, H2 2017 Pipeline by Sierra Oncology Inc, H2 2017 Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Dormant Projects, H2 2017 Discontinued Products, H2 2017
List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
